How stronger cannabis is linked to more psychiatric problems

Denmark's 23-year study reveals a troubling trend: THC potency in cannabis resin has increased nearly fourfold from 8.3% to 31.2% between 2000 and 2022. This dramatic rise in potency coincided with measurable increases in psychiatric harms at the population level, including more people seeking cannabis treatment, higher rates of cannabis-induced psychosis, and more diagnoses combining schizophrenia with cannabis use disorder. The research provides some of the strongest ecological evidence yet that stronger cannabis is linked to more serious mental health consequences across entire communities.

The study found statistically significant associations between rising THC concentrations and three major psychiatric outcomes, with the strongest effects appearing in the same year as the potency changes. Importantly, these associations held true after controlling for other factors that might influence psychiatric health. The effects were particularly pronounced in older patients and women, suggesting that certain populations may be more vulnerable to the psychiatric risks of high-potency cannabis. These findings suggest that the shift toward increasingly potent cannabis products—driven by market demand and cultivation advances—comes with genuine public health consequences.

While this ecological study cannot prove that potency changes directly cause psychiatric harm in individuals, the consistent associations across multiple outcomes and the dose-response relationship observed provide compelling evidence of a population-level risk. For consumers, these findings suggest that the modern cannabis marketplace, dominated by high-THC products, carries greater psychiatric risks than the lower-potency cannabis of previous decades, particularly for vulnerable groups like older adults and women.